Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing

Theravance Biopharma, Inc.

Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.
TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.
Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.
Cash ~$400M at end Q1 2026; no debt.
Strategic Review Committee accelerating evaluation of alternatives including potential sale of company.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theravance Biopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.

Period: the quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 19, 2026, Theravance Biopharma, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and full year ended December 31, 2025 and a business update.

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-031795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.